Abstract -A new rating scale for the quantitative assessment of the alcohol-withdrawal syndrome (AWS) was developed from the CIWA-A scale by item analysis based on the data from 132 alcoholic patients. The clinical evaluation of this AWS scale in a second sample of 256 alcoholic patients showed that it adequately assessed the course and severity of the AWS. The AWS scale provides data for a rational strategy of therapy for the AWS by rating mental and somatic symptoms on different scales, hi particular, the mental subscale allows prediction of a complicated AWS. Subjects with an AWS score > 10 at admission have a higher risk of becoming delirious than those with a lower score (46.6% vs 2.8%, P < 0.001). In order to minimize the prescription of drugs with abuse potential, such as diazepam and clomethiazole, a structured treatment programme of in-patient alcohol detoxification based on the AWS score was also developed. The comparison revealed that, in the second sample, which was treated following this protocol, the number of cases given medication was lower and the amount of clomethiazole prescribed per patient was less.
INTRODUCTION
Due to the high prevalence of alcohol abuse in most developed countries, the treatment of alcohol abusers is an increasing problem in psychiatric as well as in general hospitals. The main problems in the clinical acute management are the assessment and the treatment of alcohol withdrawal. The autonomic, mental, and neurological symptoms occurring in its course are subsumed within the alcohol-withdrawal syndrome (AWS) (Gross et al., 1973) . Clinical manifestations of AWS range on a continuum from early mild sympatomatology (i.e. anxiety, mild agitation, tremor, insomnia, mild tachycardia, and hypertension, often termed the 'tremulous state'), to more severe later manifestations (e.g. hallucinosis) or complications (i.e. seizure and arrhythmia). The most severe form of AWS is a delirium tremens with confusion and hallucinations. In view of the high costs of in-patient detoxification, mere is a debate on the suitability of those to be in-patients and those to be treated as out-patients. Since about 10% of alcoholic patients undergoing detoxification become delirious (Victor and Laureno, 1978; Wetterling et al, 1994) , the risk of complicated withdrawal must be evaluated before adequate therapeutic strategies for different forms of the AWS can be developed.
In diagnostic guidelines, such as the DSM-IV (American Psychiatric Association, 1994) and ICD-10 (World Health Organization, 1992) , items of the AWS are not defined operationally (Sellers et al., 1991) . However, some scales have been proposed for its quantitative measurement (Gross et al., 1973; Shaw et al., 1981; Kristensen et al., 1986; Sullivan et al, 1989; Banger et al., 1992) . The most widely applied is the CIWA-A scale (Shaw et al., 1981) , which is based on a scale introduced by Gross et al. (1973) . There are some revised forms of the CIWA-A scale, the CPvVA-Ar (Sullivan et al., 1989) and the CPWA-AD scales (Sellers et al, 1991) . Other scales developed by Banger et al. (1992) and Kristensen et al. (1986) contain similar items. Nevertheless, few clinical data 753 are available (Shaw et al, 1981; Naranjo et al., 1983; Sellers et al., 1983 Sellers et al., , 1991 Kristensen et al., 1986; Foy et al., 1988; Wartenberg et al., 1990) . The revised version, the CIWA-Ar (Sullivan et al.,. 1989) , has some shortcomings (Banger et al., 1992) , particularly the fact that some items are not specified at any rank. An objective rating scale should meet the following requirements: (1) shows good interobserver reliability and can be applied by trained nurses; (2) detects and quantifies all the different qualities of the AWS; (3) provides an additive score as an index of severity; (4) gives a prognosis for the course (especially in view of the need to plan a therapeutic strategy); (5) allows serial assessment; (6) is useful for assessing the response to therapy.
The present investigation consisted of three phases. The first stage aimed to derive a short assessment scale for the AWS (AWS scale) from the CIWA-A scale by means of statistical evaluation of the data from a sample of chronic alcoholic patients undergoing detoxification. The second stage examined the clinical feasibility of the new AWS scale in a second sample of alcoholic patients. The third stage compared treatment results for both samples.
PATIENTS AND METHODS

Patients
In the first stage of this investigation (development of the AWS scale), 132 chronic alcoholic patients were studied. They were admitted consecutively for detoxification to an alcohol unit of the Psychiatric Hospital at Heiligenhafen, Germany. All subjects fulfilled the DSM-HIR (American Psychiatric Association, 1987) criteria for alcohol dependence. The sample consisted of 31 women and 101 men (mean age ± SD: 44.0 ± 7.7 years). The mean (±SD) number of past detoxifications was 5.2 ± 3.9 (range 0-17).
In the second stage, the clinical feasibility of the AWS scale was tested in 256 patients with longstanding alcohol dependence according to DSM-IV criteria (American Psychiatric Association, 1994) consecutively admitted for detoxification to the psychiatric emergency ward of the General University Hospital in Liibeck. This unit specializes in the detoxification of alcoholic patients. The sample consisted of 58 women (mean age 44.9 ±7.9 years) and 198 men (mean age 43.6 ± 9.4 years). The median number of past detoxifications was 5 (range 0-29). All patients gave their informed consent before participating in this clinical study.
Methods
The CIWA-A scale was translated into German and administered to all 132 patients in the first stage. They were rated at admission and thereafter once a day at the same time of day during detoxification (maximum period 7 days) by trained students unaware of the medical treatment. The medication, in most cases clomethiazole, prescribed by clinically experienced psychiatrists without knowledge of the CIWA-A rating, was registered in the study protocol. In order to develop a new AWS scale using statistical analysis, internal consistency was proven by calculating Cronbach's a. A Cronbach's a > 0.8 was considered to demonstrate good consistency with the whole score. Furthermore, items with a corrected item score whose total score correlation r was <0.4 were excluded.
All 256 patients of the second stage were rated on the new AWS scale (Table 2) by trained nurses every 2 h. The subjects were treated according to the treatment protocol. The medication (carbamazepine or clomethiazole) was chosen according to the first rating (within 2 h of admission). In order to evaluate the inter-rater reliability, K was computed by the method of Cohen (1960) .
All statistical tests were calculated using the SPSS-PC programs (SPSS, Chicago, USA). Nonparametric statistics (Mann-Whitney U-test, X 2 -test) were used, if variables (i.e. AWS subscales) did not show a normal distribution (Kolmogorov-Smirnov test).
RESULTS
Stage 1: development of the AWS scale
Analysis of the CIWA-A scale revealed a corrected correlation of item scores and total scores (C < 0.4) for the following items (Table 1) , nausea and vomiting, tactile disturbances, auditory disturbances, hallucinations, anxiety, and convulsions. Furthermore, item analysis of the CIWA-A scale revealed that, apart from nausea and anxiety these symptoms occurred in less than 30% of the -mild AWS --moderate AWS -»-severe AWS cases. The item 'convulsions' was eliminated because cerebral seizures mostly occur within the first 24 h of the AWS (Victor, 1990 ) and the occurrence of convulsions is not a relevant predictor for the course of the AWS (Wetterling et al., 1994) . However, other rare symptoms, including hallucinations and anxiety, were judged to be clinically important for complicated alcohol withdrawal, particularly for delirium. Therefore, these items were not excluded since the aim was to assess all forms of AWS.
Stage 2: clinical feasibility of the new A WS scale
The inter-rater reliability between 20 trained nurses and three senior psychiatrists revealed K-values ranging from 0.67 to 1.00 for all 11 items listed in Table 2 . The K-value for the mental symptoms (M subscale) was 0.76 and for the somatic symptoms (S subscale) was 0.80, while the K-value for the entire AWS scale was 0.64.
The 256 cases investigated were classified according to their maximum total AWS score during withdrawal as shown in Table 3 . For further evaluation, the cases were divided into two groups according to the total AWS score at the first rating: (1) a low-risk group with a score of <10 (211 cases); (2) a high-risk group with a score of >10 (45 cases). Twenty-seven cases (10.5%) developed alcohol-withdrawal delirium (according to DSM-IV criteria). Of these subjects, 21 were high-risk patients. Thus, 46.6% of the high-risk group, but only six (2.8%) of the lowrisk group showed delirium symptoms {•/} 75.5, P < 0.001). The course of somatic and mental symptoms is recorded in Figs 1-3 . During the first 3 days, the total AWS scores as well as the AWS M subscores were significantly different between the groups (Mann-Whitney U-test, two-tailed, P < 0.01), whereas the S subscores were not. Three of six cases who developed an alcoholwithdrawal delirium (but lacking an AWS score >10 on admission) became delirious after more than 4 days of abstinence from alcohol. According to the treatment protocol nearly one-half of the patients received no medication and a further 31.6% received only carbamazepine, 22.7% needed clomethiazole or benzodiazepines. Medication was begun or changed during the course of the AWS in 19 cases (7.4%) based on changes in the AWS scale score.
AWS-M-score -*-mild AWS--moderate AWS ~-severe AWS --mild AWS--moderate AWS -severe AWS Fig. 3 . The alcohol-withdrawal syndrome (AWS) scale score for somatic symptoms.
Stage 3: comparison of the treatment results of both groups
The results of the two treatment groups are compared in Table 4 . Although the severity of the AWS was comparable, the number of subjects receiving no medication was higher in the scorecontrolled treatment group (group 2). Conversely, the number of subjects given clomethiazole, and the total dosage were much higher in the control group (group 1). The duration of drug treatment was shorter in the score-controlled group 2.
DISCUSSION
One major problem in the clinical management of the AWS is the lack of early prognostic factors for its severity. Consequently, planning an adequate treatment strategy becomes difficult. The various symptoms of the AWS can be assessed by scales. However, these scales should allow an assessment of a mild AWS as well as that with delirium. In contrast to some recently proposed scales (Sellers et al, 1991; Banger et al, 1992) developed for rating of uncomplicated alcohol withdrawal, our AWS scale aims to assess all of the different factors in the AWS including alcoholwithdrawal delirium; it thus provides a rational basis for a treatment protocol for the AWS.
Inter-rater reliability/application by trained nurses
The inter-rater reliability (given as K) between 20 trained nurses and senior psychiatrists revealed good K values, demonstrating that the AWS scale is easy to administer. Trained nurses are thus able to perform the AWS ratings.
Detection and quantification of all of the different aspects of the AWS
The most widely used scale is the CTWA-A scale, which is validated in several studies (Shaw et al., 1981; Naranjo et al., 1983; Sellers et al., 1983; Foy et al., 1988) . The CIWA-A scale has some disadvantages (Banger et al., 1992) , particularly the lack of specification of some items. The shortened revised CIWA-Ar scale (Sullivan et al., 1989) was developed by a statisticallygrounded item reduction. Like the AWS scale, it excludes the items 'seizures', 'thought disturbances', and 'flushing of face'. In contrast to the AWS scale, it also excludes the items 'quality of contact' and 'hallucinations'. However, these items are thought to be important in describing delirium tremens. They should not therefore be omitted, and are included in the AWS scale with its two subscales, one for assessing somatic symptoms, and the other for assessing mental symptoms.
Additive score as an index of severity of the AWS
As demonstrated in Fig. 1 , the total AWS score indicates the severity of the AWS quite well. Furthermore, in view of specific or alternative therapeutic strategies (see e.g. Brewer, 1995) the different courses of somatic and mental symptoms can be recorded and compared (see Figs 2 and 3) . For predominantly somatic symptomatology, some authors have recommended treatment witĥ -adrenergic blockers or clonidine (see Brewer, 1995) . For mainly mental symptoms, therapy with benzodiazepines (Shaw, 1995) or clomethiazole (Morgan, 1995) , if necessary (i.e. hallucinations) combined with haloperidol, has been recommended.
Prognosis for the course
Up until now, the predictive power of the CIWA-A scale has been proven in only a few studies (Shaw et al, 1981; Naranjo et al, 1983; Sellers et al, 1983; Foy et al, 1988) . Our results agree very well with those of Foy et al. (1988) , who reported a cut-off value of 15 on the CIWA-A scale. The cases with values > 15 ran a high risk of developing a complicated AWS. Our data reveal that the first AWS score delivers an early prognosis for the course of AWS. Bias by treatment effects could be excluded, since all cases received standardized treatment. Six cases who developed alcohol-withdrawal delirium had a first AWS scale score <10. Most of these cases could still be identified by the subscale M on the day of admission (AWS-M subscale >5). However, three subjects became delirious after more than 4 days of abstinence from alcoholic beverages. It is probable that these patients also abused other drugs (e.g. benzodiazepines).
Serial assessment
Serial assessment of the AWS score provides data for planning therapy, indicating in our sample the need for medication or a change of drug in 19 cases according to defined cut-off values (increase of the total AWS score by more than 5 within 24 h or increase of score to over 10).
Therapy response
The AWS scale yields sound information on response to therapy, since the efficiency of treatment is demonstrated by a rapid and progressive decrease in the AWS score (see Figs 1-3 ). An insufficient response to therapy is indicated by an increase in the AWS score. In these cases, a change of medication is recommended.
The AWS scale can also be used to reduce the dose of medication used to treat withdrawal. Given the risk of dependence on the drugs used in the treatment of the AWS (benzodiazepines and clomethiazole), the number of alcoholic patients receiving these drugs should be minimized. As demonstrated in our study, this goal can be achieved by applying a standardized treatment protocol. Nearly one-half of the patients received no medication and a further 31.6% received only carbamazepine. Only 22.6% needed clomethiazole to cope with their AWS. The comparison with the first group treated by experienced psychiatrists in a specialized ward (group 1) revealed that the number of cases, as well as the administered dosage of clomethiazole, could be reduced in the score-controlled treatment group (Table 4) . Wartenberg et al., (1990) also reported that a staff training programme using a protocol based on the CIWA-Ar scale resulted in a marked decrease in the number of alcoholics receiving drugs for AWS. To date, no clinical validation study of the more compact form of the original CIWA-A, the CIWA-AD (Sellers et al., 1991) , has been published.
In summary, our results show that the new AWS scale developed from the CIWA-A scale allows quantitative measurement of the AWS. It is short and easy to administer. The subscales S for somatic features and M for mental symptoms provide data for a rational strategy of therapy for both major forms of AWS -the tremulous and the hallucinatory states. As our results show, a simple treatment protocol (mild AWS: no medication; moderate AWS: carbamazepine up to 900mg/day; severe AWS: clomethiazole) proved sufficient treatment for the AWS.
